Aptose Biosciences to Present at Oppenheimer 33rd Annual Healthcare Conference
Aptose Biosciences (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology firm, announced its participation in the Oppenheimer 33rd Annual Healthcare Conference, scheduled for March 13-15, 2023. The company’s Chairman and CEO, William G. Rice, Ph.D., will engage in a fireside chat on March 13 from 12:40 – 1:10 PM ET alongside Oppenheimer's Senior Analyst, Matthew Biegler. An audio webcast of the event will be available shortly after the live session and can be accessed via Aptose’s website. Additionally, the Aptose management team will conduct virtual one-on-one meetings during the conference.
- None.
- None.
SAN DIEGO and TORONTO, March 02, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase inhibitors to treat hematologic malignancies, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will participate in the Oppenheimer 33rd Annual Healthcare Conference being held March 13-15, 2023, in a virtual format.
| Oppenheimer 33rd Annual Healthcare Conference | ||
| Presentation Details: | ||
| Date: | Monday, March 13, 2023 | |
| Time: | 12:40 – 1:10 PM ET | |
| Format: | Fireside Chat - William G. Rice, PhD, Chairman, President and Chief Executive Officer, Aptose, with Matthew Biegler, Senior Analyst, Emerging Biotechnology, Oppenheimer | |
| Webcast: | LINK | |
The audio webcast will be archived shortly after the live event and will be available through the Aptose website, www.aptose.com.
The Aptose management team will be hosting virtual one-on-one meetings during the conference. To schedule a one-on-one meeting, please contact your conference representative.
About Aptose
Aptose Biosciences is a clinical-stage biotechnology company committed to developing precision medicines addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage oral kinase inhibitors under development for hematologic malignancies: tuspetinib (formerly HM43239), an oral, myeloid kinase inhibitor in an international Phase 1/2 trial in patients with relapsed or refractory acute myeloid leukemia (AML); and luxeptinib, an oral, dual lymphoid and myeloid kinase inhibitor in Phase 1 a/b stage development for the treatment of patients with relapsed or refractory hematologic malignancies. For more information, please visit www.aptose.com.
| For further information, please contact: | ||
| Aptose Biosciences Inc. | LifeSci Advisors, LLC | |
| Susan Pietropaolo | Dan Ferry, Managing Director | |
| Investor Relations | 617-535-7746 | |
| 201-923-2049 | Daniel@LifeSciAdvisors.com | |
| spietropaolo@aptose.com | ||
FAQ
When is Aptose participating in the Oppenheimer 33rd Annual Healthcare Conference?
What time is William G. Rice's presentation at the Oppenheimer conference?
How can I access the audio webcast of the Aptose presentation?
What is the focus of Aptose Biosciences?
What are the clinical-stage products Aptose is developing?
